Találati lista | Tudóstér

001-es BibID:	BIBFORM131823
035-os BibID:	(WoS)001542583400001
Első szerző:	Domingo-Domenech, Eva
Cím:	Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma : subgroup analysis of the ECHELON-2 study at 5 years' follow-up / Eva Domingo-Domenech, Steven Horwitz, Barbara Pro, Tim Illidge, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage
Dátum:	2025
ISSN:	2044-5385
Tárgyszavak:	Orvostudományok Klinikai orvostudományok levél folyóiratcikk Brentuximab Echelon-2 cell lymphoma
Megjelenés:	Blood Cancer Journal. - 15 : 1 (2025), p. 1-5. -
További szerzők:	Horwitz, Steven Pro, Barbara Illidge, Tim Trumper, Lorenz Iyer, Swami Advani, Ranjana Bartlett, Nancy L. Christensen, Jacob Haaber Kim, Won Seog Feldman, Tatyana Choi, Ilseung Gritti, Giuseppe Belada, David Shustov, Andrei Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Zinzani, Pier Luigi Hüttmann, Andreas Trneny, Marek Le Gouill, Steven Jagadeesh, Deepa Friedberg, Jonathan W. Little, Meredith Dong, Cassie Fanale, Michelle Fenton, Keenan Savage, Kerry J.
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon:

001-es BibID:	BIBFORM120740
035-os BibID:	(Scopus)85122922204 (WOS)000755659500008
Első szerző:	Horwitz, Steven
Cím:	The ECHELON-2 Trial : 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma / S. Horwitz, O. A. O`Connor, B. Pro, L. Trümper, S. Iyer, R. Advani, N. L. Bartlett, J. H. Christensen, F. Morschhauser, E. Domingo-Domenech, G. Rossi, W. S. Kim, T. Feldman, T. Menne, D. Belada, Á. Illés, K. Tobinai, K. Tsukasaki, S.-P. Yeh, A. Shustov, A. Hüttmann, K. J. Savage, S. Yuen, P. L. Zinzani, H. Miao, V. Bunn, K. Fenton, M. Fanale, M. Puhlmann, T. Illidge
Dátum:	2022
ISSN:	0923-7534 1569-8041
Megjegyzések:	Background: For patients with peripheral T-cell lymphoma (PTCL), outcomes using frontline treatment with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like therapy are typically poor. The ECHELON-2 study demonstrated that brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (A CHP) exhibited statistically superior progression-free survival (PFS) per independent central review and improvements in overall survival versus CHOP for the frontline treatment of patients with systemic anaplastic large cell lymphoma or other CD30-positive PTCL. Patients and methods: ECHELON-2 is a double-blind, double-dummy, randomized, placebo-controlled, active-comparator phase III study. We present an exploratory update of the ECHELON-2 study, including an analysis of 5-year PFS per investigator in the intent-to-treat analysis group. Results: A total of 452 patients were randomized (1 : 1) to six or eight cycles of A+CHP (N = 226) or CHOP (N = 226). At median follow-up of 47.6 months, 5-year PFS rates were 51.4% [95% confidence interval (CI): 42.8% to 59.4%] with A+CHP versus 43.0% (95% CI: 35.8% to 50.0%) with CHOP (hazard ratio = 0.70; 95% CI: 0.53-0.91), and 5-year overall survival (OS) rates were 70.1% (95% CI: 63.3% to 75.9%) with A+CHP versus 61.0% (95% CI: 54.0% to 67.3%) with CHOP (hazard ratio = 0.72; 95% CI: 0.53-0.99). Both PFS and OS were generally consistent across key subgroups. Peripheral neuropathy was resolved or improved in 72% (84/117) of patients in the A+CHP arm and 78% (97/124) in the CHOP arm. Among patients who relapsed and subsequently received brentuximab vedotin, the objective response rate was 59% with brentuximab vedotin retreatment after A+CHP and 50% with subsequent brentuximab vedotin after CHOP. Conclusions: In this 5-year update of ECHELON-2, frontline treatment of patients with PTCL with A+CHP continues to provide clinically meaningful improvement in PFS and OS versus CHOP, with a manageable safety profile, including continued resolution or improvement of peripheral neuropathy.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk brentuximab vedotin CHOP frontline treatment overall survival peripheral T-cell lymphoma randomized clinical trial
Megjelenés:	Annals Of Oncology. - 33 : 3 (2022), p. 288-298. -
További szerzők:	O'Connor, Owen A. Pro, Barbara Trümper, Lorenz Iyer, Swaminathan Advani, Ranjana Bartlett, Nancy L. Christensen, Jacob Haaber Morschhauser, Franck Domingo-Domenech, Eva Rossi, Giuseppe Kim, Won-Seok Feldman, Tatyana Menne, T. Belada, David Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Tobinai, Kensei Tsukasaki, Kunihiro Yeh, Su-Peng Shustov, Andrei Hüttmann, Andreas Savage, Kerry J. Yuen, Sam Zinzani, Pier Luigi Miao, Harry Bunn, V. Fenton, Keenan Fanale, Michelle Puhlmann, M. Illidge, Tim
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM077363
035-os BibID:	(WoS)000456000000026 (Scopus)85059506213
Első szerző:	Horwitz, Steven
Cím:	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trial / Steven Horwitz, Owen A. O'Connor, Tim Illidge, Michelle Fanale, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana Feldman, Anne Lennard, David Belada, Árpád Illés, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei Shustov, Andreas Hüttmann, Kerry J. Savage, Sam Yuen, Swaminathan Iyer, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Trümper, ECHELON-2 Study Group
Dátum:	2019
ISSN:	2352-3026
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk
Megjelenés:	The Lancet Haematology. - 393 : 10168 (2019), p. 229-240. -
További szerzők:	O'Connor, Owen A. Illidge, Tim Fanale, Michelle Advani, Ranjana Bartlett, Nancy L. Christensen, Jacob Haaber Morschhauser, Franck Domingo-Domenech, Eva Rossi, Giuseppe Kim, Won Seog Feldman, Tatyana Lennard, Anne Belada, David Illés Árpád (1959-) (belgyógyász, haematológus, onkológus) Tobinai, Kensei Tsukasaki, Kunihiro Yeh, Su-Peng Shustov, Andrei Hüttmann, Andreas Savage, Kerry J. Yuen, Sam Iyer, Swaminathan Zinzani, Pier Luigi Hua, Zhaowei Little, Meredith Rao, Shangbang Woolery, Joseph Manley, Thomas Trümper, Lorenz ECHELON-2 Study Group
Internet cím:	Intézményi repozitóriumban (DEA) tárolt változat DOI
Borító:
Saját polcon: